Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
news
2022-06-03 00:00:00

SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. ('Sutro' or the 'Company') (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer therapeutics, today announced that on June 3, 2022, the Compensation Committee of Sutro's Board of Directors granted 75,000 shares of Sutro Biopharma stock options and 80,000 Restricted Stock Units of Sutro common stock to three new employees.
